GHRP-6 Peptide: Dosage Chart, Benefits & Hunger

Research protocols center on 100 mcg per injection because that is where the dose-response curve flattens. In the original human work, GH release scaled with dose up to about 1 mcg/kg intravenously, and the foundational study documented strong GH pulses in normal men at exactly that threshold (Bowers et al., J Clin Endocrinol Metab, 1990, PMID 2108187).

Timing decides how much of each dose converts to GH. Insulin and fatty acids blunt the pulse, so protocols inject on an empty stomach and hold food for 20 to 30 minutes afterward. The three classic windows are waking, post-training, and before bed, which ride the body's natural GH rhythm.

Doubling past saturation does not double output. A 100 kg subject injecting 300 mcg instead of 100 mcg gets a modestly taller GH pulse but roughly triple the hunger signal, plus measurable cortisol and prolactin elevation that the 100 mcg dose largely avoids. The extra 200 mcg mostly buys side effects.

A 5 mg vial reconstituted with 2.5 mL of bacteriostatic water yields 100 mcg per 5 units on an insulin syringe. Getting that arithmetic wrong is the most expensive mistake in the protocol, so run the numbers through the peptide reconstitution calculator and cross-check syringe markings with the peptide unit converter.

GHRP-6 is a synthetic chain of six amino acids (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) built in the 1980s by Cyril Bowers' group, years before anyone knew which receptor it hit. It reliably released growth hormone in humans, and the mystery of how drove a decade of research.

The answer came in two acts. In 1996, researchers cloned the receptor GHRP-6 activates, the growth hormone secretagogue receptor in the pituitary and hypothalamus (Howard et al., Science, 1996, PMID 8688086). In 1999, Kojima's team found the body's own key for that lock: ghrelin, the stomach hormone that drives hunger and GH release (Kojima et al., Nature, 1999, PMID 10604470).

Think of the pituitary as a house with two doorbells. GHRH analogs like CJC-1295 ring the front door, and ghrelin mimetics ring the back. GHRP-6 is literally a copy of the back-door key: it binds the same ghrelin receptor, which is why every injection arrives with an appetite surge that selective relatives like ipamorelin were later engineered to avoid.

The practical consequence: GHRP-6 triggers a sharp, short GH pulse rather than a sustained elevation. The pulse peaks within about 30 minutes and returns to baseline within a few hours, which mimics natural secretion instead of flatlining it the way exogenous HGH does.

Every GH peptide in this family trades potency against side effects. GHRP-6 sits in the middle: stronger hunger than any of them, moderate GH release, mild cortisol and prolactin activity at higher doses.

Within the ghrelin mimetics, the choice is a hunger question. Ipamorelin skips the appetite surge almost entirely, which is why it dominates modern stacks; the MK-677 vs ipamorelin comparison walks through the oral alternative. Hexarelin dosing buys more GH per mcg but desensitizes faster and pushes cortisol hardest.

The GHRH analogs are a different doorbell entirely. They cannot replace a GHRP, and a GHRP cannot replace them; the tesamorelin vs ipamorelin breakdown and the CJC-1295 vs sermorelin guide map that side of the family.

GHRP-6 hunger is not a vague appetite lift. It arrives 15 to 20 minutes after injection, feels like genuine stomach-empty hunger, and typically lasts 30 to 60 minutes. Subjects who inject 200 to 300 mcg report it as difficult to ignore.

The mechanism is direct receptor math. GHRP-6 activates the same receptor as ghrelin, and in controlled human research a ghrelin infusion increased food intake at a buffet meal by 28 percent (Wren et al., J Clin Endocrinol Metab, 2001, PMID 11739476). An injection of its mimetic pulls the same lever on demand.

Whether that is a bug or a feature depends on the research goal. In bulking and appetite-recovery contexts the hunger is the point: a pre-meal injection makes a 1,000-calorie meal feel easy. In fat-loss contexts it is disqualifying, which is why cutting-phase protocols swap in ipamorelin and accept a slightly weaker pulse.

One practical failure mode: injecting GHRP-6 before bed on a strict diet, then eating 500 unplanned calories at midnight because the hunger won. That single response erases the caloric edge the GH pulse provided. If the diet cannot absorb an appetite spike, this is the wrong peptide.

The two-doorbell design is why stacking exists. Human data shows GHRP-6 needs endogenous GHRH tone to reach maximal GH stimulation (Pandya et al., J Clin Endocrinol Metab, 1998, PMID 9543138), and Bowers' original work found the combination acts synergistically: GHRP plus GHRH releases more GH than the sum of either alone (PMID 2108187).

The standard research pairing is 100 mcg GHRP-6 plus 100 mcg CJC-1295 without DAC in the same syringe, 1 to 3x daily on an empty stomach. The CJC-1295 dosage guide covers the GHRH side in detail, and the no-DAC guide explains why the short-acting version matches GHRP-6's pulse profile.

The DAC version changes the logic. Its multi-day half-life provides constant GHRH tone, so a once- or twice-weekly DAC injection with daily GHRP-6 shots is a lower-injection-count alternative. Same receptors, different rhythm.

Most of the published stack literature on this site covers CJC-1295 with ipamorelin because that combination skips the hunger; the benefits rundown applies almost unchanged to GHRP-6 apart from the appetite surge. Model the combined math with the CJC-1295/ipamorelin dosage calculator, substituting GHRP-6 on the GHRP side.

GHRP-6 has decades of small human studies with a mostly mild acute profile, and zero long-term safety trials. Both halves of that sentence matter.

The documented effects are dose-dependent. Hunger hits nearly everyone. Water retention, tingling or flushed skin, and injection-site redness are common in the first weeks. Above roughly 1 to 2 mcg/kg, cortisol and prolactin rise measurably; at 100 mcg those elevations are small and transient, which is another argument for staying at saturation rather than above it.

Two quantified scenarios worth internalizing. A subject running 300 mcg three times daily (900 mcg/day, roughly triple saturation for a 90 kg person) gains 2 to 3 kg of water weight in the first two weeks and elevates prolactin enough to blunt libido; dropping back to 100 mcg doses resolves both within days. A diabetic-leaning subject injecting before a carb-heavy meal compounds GH-induced insulin resistance, since GH is a counter-regulatory hormone that raises blood glucose for hours after each pulse.

Desensitization is the other ceiling. Continuous high-dose exposure downregulates the receptor within weeks, which is why protocols pulse doses rather than infuse and why 8 to 12 week cycles with breaks are standard. The side-effect patterns catalogued in the CJC-1295 and ipamorelin side effects guide overlap heavily, minus the hunger.

GHRP-6 is not FDA approved for any indication, and it is banned by WADA for competitive athletes. Anyone with a history of cancer should treat GH-axis peptides as off-limits, since GH and IGF-1 accelerate cell growth indiscriminately. A qualified physician and baseline bloodwork belong in any serious protocol.

Four errors account for most failed GHRP-6 protocols. Each one is measurable, and each one has a simple fix.

Injecting after food. A dose taken 30 minutes after a meal lands on elevated insulin and fatty acids, which can cut the GH pulse by half or more. The subject pays for 100 mcg and absorbs the hormonal benefit of far less. Fix: inject fasted, then hold food for 20 to 30 minutes.

Chasing dose instead of frequency. One 300 mcg injection daily produces one saturated pulse plus surplus hunger and cortisol. Three 100 mcg injections produce three full pulses from the same 300 mcg of material. Frequency multiplies output; dose past saturation does not.

Reconstitution math errors. Adding 1 mL instead of 2.5 mL to a 5 mg vial makes each unit on the syringe worth 2.5x the intended dose, so a planned 100 mcg becomes 250 mcg. The result is a week of runaway appetite blamed on the peptide instead of the dilution. Fix: write the concentration on the vial and verify with the peptide reconstitution calculator.

Running it solo when the goal is maximal GH. GHRP-6 without GHRH tone leaves the documented synergy on the table (PMID 2108187). A matched 100 mcg of CJC-1295 without DAC roughly doubles the pulse for a few dollars more per dose.

A fifth, quieter mistake is skipping breaks. Receptor desensitization builds over continuous weeks of exposure, so the 8 to 12 week cycle with a 4 week gap is what keeps month three as productive as month one.